Recro Pharma has presented the additional results from its Phase II clinical trial of Dex-IN, an intranasal formulation of dexmedetomidine, to treat acute pain in adult patients undergoing bunionectomy surgery.

Bunionectomy surgery involves an incision on the top or side of the big toe joint and the removal or realignment of soft tissue and bone.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Dex-IN previously reached the primary endpoint of the clinical study, showing significant pain relief compared against placebo over 48 hours.

The Phase II trial was a randomised, multicentre, double-blind, and placebo-controlled trial designed to assess the efficacy and safety of the firm’s proprietary intranasal formulation of dexmedetomidin Dex-IN in adult patients undergoing bunionectomy surgery.

"Patients have been randomised to either a 50ug dose of Dex-IN or a placebo intranasal dose given every six hours."

In the trial, patients have been randomised to either a 50ug dose of Dex-IN or a placebo intranasal dose given every six hours.

The company randomised 168 patients in the trial. In each treatment group 84 patients received medication in the study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Patients remained under observation for 48 hours at study centres, following the beginning of treatment. They were followed for seven days after the initial dose of study medication.

According to the firm, the primary efficacy endpoint of the trial was the summed pain intensity difference over 48 hours, SPID48, using the last observation carry forward analysis method.

Additional efficacy endpoints comprised use of opioid rescue medication and SPIDs over various time intervals, as well as other standard efficacy analyses.